Clinical trial
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
NCT00287846 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00287846 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis |
| Official title | Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy |
| Lead sponsor | UNICANCER, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Desmoid Tumor |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 40 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Jun 1, 2010 |
| First posted | Feb 7, 2006 |
| Last update posted | Aug 30, 2016 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: